VERTEX PHARMACEUTICAL COM STK USD0.01VV

VERTEX PHARMACEUTICAL COM STK USD0.01

491.50USDD
+6.60+1.36%
At close at Mar 5, 20:08 GMT
USD
No trades
See on Supercharts

0QZU fundamentals

Key facts

Market capitalization‪124.86 B‬USD
Basic EPS (TTM)−2.07USD
Founded1989
Employees (FY)‪6.1 K‬
CEOReshma Kewalramani
Websitevrtx.com
About

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Ownership
‪‪256.79 M‬‬
Free Float shares
‪‪255.95 M‬‬ (99.67%)
Closely held shares
‪‪842.27 K‬‬ (0.33%)
Free Float shares
‪‪255.95 M‬‬ (99.67%)
Closely held shares
‪‪842.27 K‬‬ (0.33%)
Capital structure
Market cap
‪‪124.86 B‬‬
Debt
‪‪1.75 B‬‬
Cash & equivalents
‪‪6.12 B‬‬
Enterprise value
‪‪120.49 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪124.86 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
11.50x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
11.50x
Valuation ratios
‪0.00‬
‪3.00‬
‪6.00‬
‪9.00‬
‪12.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪8.00‬
‪16.00‬
‪24.00‬
‪32.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−150%‬
‪−100%‬
‪−50%‬
‪0%‬
‪50%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−4.00 B‬‬
‪‪−2.00 B‬‬
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Pharmaceuticals
By country
Period: 2024
United States
Europe
Other

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬
Actual
Estimate
Earnings
Next:Apr 30, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−15.00‬
‪−10.00‬
‪−5.00‬
‪0.00‬
‪5.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

0QZU does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−4.00 B‬‬
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬
Assets
Liabilities